References
Simpson D, Perry CM. Atomoxetine. Pediatr Drugs 2003; 5(6): 407–15
Elia J. Atomoxetine: a viewpoint. Pediatr Drugs 2003; 5(6): 416
Safer DJ. Atomoxetine: a viewpoint. Pediatr Drugs 2003; 5(6): 416–7
Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996 Apr; 35: 409–32
Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002 Dec; 63(12): 1140–7
Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002 Nov; 159(11): 1896–901
Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001 Nov; 108(5):E83–91
Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002; 63 Suppl. 12: 50–5
Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002 Jul 1; 67(2): 149–56
Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002 Jul; 41(7): 776–84
Kratochvil C, Wernicke JF, Michelson D, et al. Long-term safety of atomoxetine in the treatment of ADHD [abstract]. 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2001 Oct 23–28; Honolulu, 119
Atomoxetine (Strattera) for ADHD. Med Lett Drugs Ther 2003 Feb 3; 45 (1149): 11–2
Greenhill LL, Findling RL, Swanson JM. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002 Mar; 109: E39
Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, parallel group study of SL1381 (Adderal XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 2002 Mar; 110: 258–66
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Elia, J., Safer, D.J. Atomoxetine: profile report. Drugs Ther. Perspect 19, 5–7 (2003). https://doi.org/10.2165/00042310-200319100-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200319100-00002